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The discovery of a range of brain and glial directed autoantibodies has allowed 
clinicians to associate these antibodies to specific neurological syndromes;
(1)
 and 
have additionally started to unify past and present clinically identical neurological 
syndromes. For example, the intriguing polysymptomatic eponymous Sébire 
encephalitis is now acknowledged by many to be anti–N-methyl-D-aspartate 
receptor (NMDAR) encephalitis.
(2)
 50 years after Lord Brain first described 
Hashimoto’s Encephalopathy (HE), a disorder characterized by diverse neurological 
dysfunction with associated elevated anti-thyroid antibodies, Chen et al. describe a 
child with an inflammatory encephalopathy in whom both anti-thyroid and myelin 
oligodendrocyte glycoprotein (MOG) autoantibodies were identified.
(3)
   
 
Whilst there has been agreement amongst clinicians on the existence of a neurologic 
syndrome associated with thyroid antibodies; and its clinical response to steroid 
therapy alongside association with other autoimmune diseases suggesting an 
immune mediated central nervous system disorder, there remains significant doubt 
of the pathogenic role of thyroid antibodies.
(4)
 Similarly, although MOG antibody 
appear to mediate clinical and radiological phenotype of demyelination that is 
distinguishable from multiple sclerosis,
(5)
 the precise mechanistic effects of 
antibodies are not resolved.  Nonetheless, it is plausible that MOG, expressed in the 
outermost lamella of the myelin sheath, may either be a primary target of 
autoimmunity or may become exposed in any brain inflammation, particularly in 
those in whom myelin inflammation is ongoing. Thus, the main clinical question this 
child with a neurological syndrome and two antibodies identified is if the patient 
may have HE and MOG-associated brain inflammation concurrently or either HE or 
MOG associated brain inflammation with the respective other antibody not 
contributing to the neurologic syndrome. 
 
The co-occurrence of auto-immune syndromes in patients is recognised and may 
target multi-organs or a single organ in multiple ways. Examples of brain directed 
autoimmunity co-occurring with systemic auto-immunity, as has been proposed in 
this case, and/or across a timeline are reported and would not be novel to clinicians. 
Importantly, we are starting to recognise that some co-occurrence may cluster more 
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frequently such as myasthenia gravis with neuromyelitis optica;
(6)
 or more 
specifically, MOG-antibody associated demyelination syndrome that may occur 
before, during or after anti-NMDAR encephalitis. 
(7)
 
 
The specificity of thyroid antibodies in predicting a neurological syndrome is limited 
as these autoantibodies are frequently also present in the general population 
without thyroid associated disease.
(4)
 A positive thyroid auto-antibody in the 
presence of encephalopathy may lead to the clinical diagnosis of HE, potentially in 
the context of a yet to be tested or identified pathogenic brain directed 
autoimmunity. The case reported by Chen et al 
(3)
, alongside previously reported 
cases of HE sharing very distinct phenotypic similarity to cases of anti-MOG antibody 
associated demyelination, as review by the authors, raises the important question if 
a subset cases of HE are actually MOG antibody mediated disease.  
 
Future identification of other neuronal surface antibodies are likely to define the 
precise target of autoimmunity in other previously recognised neurological 
syndromes. Importantly, care still needs to be given to establishing the clinical 
relevance and treatment implications of identification of these antibodies, including 
MOG antibodies. 
  
  
 
Disclosures: Dr Ming Lim receives research grants from Action Medical Research, 
DES society, GOSH charity, NIHR, MS Society, SPARKS charity and; receives research 
support grants from the London Clinical Research Network and Evelina Appeal; has 
received consultation fees from CSL Behring; received travel grants from Merck 
Serono; and awarded educational grants to organize meetings by Novartis, Biogen 
Idec, Merck Serono and Bayer. Dr Thomas Rossor has no conflicts of interest. 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
References 
 
1. Lim M, Gorman M. Autoimmune neurologic disorders in children. Handb 
Clin Neurol. 2016; 133: 485-510. 
2. Sebire G. In search of lost time from "Demonic Possession" to anti-N-
methyl-D-aspartate receptor encephalitis. Ann Neurol. 2010; 67: 141-142; 
author reply 142-143. 
3. Chen K-A, Brilot F, Dale RC, Lafferty AR, Andrews PI. Hashimoto's 
encephalopathy and anti-MOG antibody encephalitis: 50 years after Lord 
Brain's description. Eur J Paediatr Neurol (In Press). 
4. Schiess N, Pardo CA. Hashimoto's encephalopathy. Ann N Y Acad Sci. 
2008; 1142: 254-265. 
5. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing 
acquired demyelinating syndromes in children. Neurology. 2017. 
6. Jarius S, Paul F, Franciotta D, et al. Neuromyelitis optica spectrum 
disorders in patients with myasthenia gravis: ten new aquaporin-4 
antibody positive cases and a review of the literature. Mult Scler. 2012; 
18: 1135-1143. 
7. Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating 
syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann 
Neurol. 2014; 75: 411-428. 
 
 
